Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.35
PCRX's Cash-to-Debt is ranked lower than
56% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. PCRX: 1.35 )
Ranked among companies with meaningful Cash-to-Debt only.
PCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.47 Max: No Debt
Current: 1.35
0.25
No Debt
Equity-to-Asset 0.46
PCRX's Equity-to-Asset is ranked lower than
75% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. PCRX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
PCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.45 Max: 0.66
Current: 0.46
-0.82
0.66
Debt-to-Equity 0.95
PCRX's Debt-to-Equity is ranked lower than
84% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. PCRX: 0.95 )
Ranked among companies with meaningful Debt-to-Equity only.
PCRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.29  Med: 0.67 Max: 2.8
Current: 0.95
-1.29
2.8
Debt-to-EBITDA 10.14
PCRX's Debt-to-EBITDA is ranked lower than
95% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. PCRX: 10.14 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PCRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.1  Med: -1.03 Max: 24.84
Current: 10.14
-23.1
24.84
Interest Coverage 0.70
PCRX's Interest Coverage is ranked lower than
99% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. PCRX: 0.70 )
Ranked among companies with meaningful Interest Coverage only.
PCRX' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 1.33 Max: 1.33
Current: 0.7
0.7
1.33
Piotroski F-Score: 6
Altman Z-Score: 3.90
Beneish M-Score: -2.79
WACC vs ROIC
10.78%
6.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.28
PCRX's Operating Margin % is ranked lower than
67% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. PCRX: 4.28 )
Ranked among companies with meaningful Operating Margin % only.
PCRX' s Operating Margin % Range Over the Past 10 Years
Min: -325.77  Med: -94.21 Max: 4.28
Current: 4.28
-325.77
4.28
Net Margin % -1.30
PCRX's Net Margin % is ranked lower than
71% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. PCRX: -1.30 )
Ranked among companies with meaningful Net Margin % only.
PCRX' s Net Margin % Range Over the Past 10 Years
Min: -300.62  Med: -104.24 Max: 0.75
Current: -1.3
-300.62
0.75
ROE % -1.47
PCRX's ROE % is ranked lower than
68% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. PCRX: -1.47 )
Ranked among companies with meaningful ROE % only.
PCRX' s ROE % Range Over the Past 10 Years
Min: -558.91  Med: -17.35 Max: 0.95
Current: -1.47
-558.91
0.95
ROA % -0.66
PCRX's ROA % is ranked lower than
65% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. PCRX: -0.66 )
Ranked among companies with meaningful ROA % only.
PCRX' s ROA % Range Over the Past 10 Years
Min: -82.83  Med: -45.86 Max: 0.52
Current: -0.66
-82.83
0.52
ROC (Joel Greenblatt) % 11.44
PCRX's ROC (Joel Greenblatt) % is ranked lower than
59% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. PCRX: 11.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -251.5  Med: -108.44 Max: 11.44
Current: 11.44
-251.5
11.44
3-Year Revenue Growth Rate 8.70
PCRX's 3-Year Revenue Growth Rate is ranked higher than
61% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PCRX: 8.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: 42.3 Max: 80.4
Current: 8.7
-66.9
80.4
3-Year EPS without NRI Growth Rate -40.00
PCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. PCRX: -40.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 47.1 Max: 68.6
Current: -40
0
68.6
GuruFocus has detected 4 Warning Signs with Pacira Pharmaceuticals Inc PCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PCRX's 30-Y Financials

Financials (Next Earnings Date: 2019-03-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

PCRX Guru Trades in Q3 2017

Jim Simons 374,500 sh (+2003.93%)
Steven Cohen 1,084,886 sh (+537.42%)
Mariko Gordon 1,222,655 sh (+8.98%)
Eaton Vance Worldwide Health Sciences Fund 205,136 sh (+59.96%)
Steven Cohen 782,200 sh (unchged)
Ken Fisher Sold Out
Paul Tudor Jones Sold Out
Ron Baron Sold Out
» More
Q4 2017

PCRX Guru Trades in Q4 2017

Ken Fisher 5,282 sh (New)
Jim Simons 509,900 sh (+36.15%)
Mariko Gordon 1,230,854 sh (+0.67%)
Steven Cohen 150,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 205,136 sh (unchged)
Steven Cohen 501,000 sh (-53.82%)
» More
Q1 2018

PCRX Guru Trades in Q1 2018

Jim Simons Sold Out
Ken Fisher Sold Out
Mariko Gordon 1,137,220 sh (-7.61%)
Steven Cohen 11,700 sh (-97.66%)
Eaton Vance Worldwide Health Sciences Fund 135,553 sh (-33.92%)
» More
Q2 2018

PCRX Guru Trades in Q2 2018

Paul Tudor Jones 33,192 sh (New)
Steven Cohen 101,636 sh (+768.68%)
Mariko Gordon 1,181,250 sh (+3.87%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:PCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSX:APH, BOM:524494, SZSE:002435, NAS:IPXL, TSE:4547, NAS:RDUS, NAS:ENDP, SZSE:300485, SZSE:002550, ROCO:6446, SHSE:600557, TSE:4569, SHSE:600993, XBRU:FAGR, XKRX:003520, BOM:533573, SZSE:300725, SZSE:300401, SHSE:600750, TSX:LEAF » details
Traded in other countries:82P.Germany,
Headquarter Location:USA
Pacira Pharmaceuticals Inc is a specialty and generic drug manufacturing company. The company develops, manufactures, and commercializes pharmaceutical products for use in hospitals and ambulatory surgery centers across the United States.

Pacira Pharmaceuticals is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and commercialization of pharmaceutical products, primarily for use in hospitals and ambulatory surgery centers. The company focuses its product candidates within the United States, and intends to out-license commercialization rights for other territories. Pacira aims to retain significant control over the development process and commercial execution for its product candidates.

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on PaciraPharmaceuticals - Jan 18, 2017

Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay.



From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
Forward PE Ratio 46.08
PCRX's Forward PE Ratio is ranked lower than
92% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. PCRX: 46.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.45
PCRX's PB Ratio is ranked lower than
82% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. PCRX: 6.45 )
Ranked among companies with meaningful PB Ratio only.
PCRX' s PB Ratio Range Over the Past 10 Years
Min: 3.47  Med: 7.73 Max: 73.42
Current: 6.45
3.47
73.42
PS Ratio 6.03
PCRX's PS Ratio is ranked lower than
72% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. PCRX: 6.03 )
Ranked among companies with meaningful PS Ratio only.
PCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.5  Med: 10.15 Max: 30.46
Current: 6.03
0.5
30.46
Price-to-Free-Cash-Flow 71.41
PCRX's Price-to-Free-Cash-Flow is ranked lower than
94% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. PCRX: 71.41 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PCRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 66.68  Med: 209.11 Max: 1380.35
Current: 71.41
66.68
1380.35
Price-to-Operating-Cash-Flow 43.55
PCRX's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. PCRX: 43.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PCRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.8  Med: 76.7 Max: 894.45
Current: 43.55
33.8
894.45
EV-to-EBIT 118.49
PCRX's EV-to-EBIT is ranked lower than
97% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. PCRX: 118.49 )
Ranked among companies with meaningful EV-to-EBIT only.
PCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -729.5  Med: -14.9 Max: 593
Current: 118.49
-729.5
593
EV-to-EBITDA 65.05
PCRX's EV-to-EBITDA is ranked lower than
95% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. PCRX: 65.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
PCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1861.8  Med: -11.9 Max: 970.6
Current: 65.05
-1861.8
970.6
EV-to-Revenue 5.73
PCRX's EV-to-Revenue is ranked lower than
70% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. PCRX: 5.73 )
Ranked among companies with meaningful EV-to-Revenue only.
PCRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 10.9 Max: 31
Current: 5.73
2.5
31
Current Ratio 8.66
PCRX's Current Ratio is ranked higher than
89% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. PCRX: 8.66 )
Ranked among companies with meaningful Current Ratio only.
PCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.17 Max: 10.16
Current: 8.66
0.81
10.16
Quick Ratio 7.83
PCRX's Quick Ratio is ranked higher than
89% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. PCRX: 7.83 )
Ranked among companies with meaningful Quick Ratio only.
PCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.07 Max: 9.31
Current: 7.83
0.68
9.31
Days Inventory 179.99
PCRX's Days Inventory is ranked lower than
74% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. PCRX: 179.99 )
Ranked among companies with meaningful Days Inventory only.
PCRX' s Days Inventory Range Over the Past 10 Years
Min: 31.07  Med: 83.87 Max: 230.95
Current: 179.99
31.07
230.95
Days Sales Outstanding 38.93
PCRX's Days Sales Outstanding is ranked higher than
82% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. PCRX: 38.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.85  Med: 40.48 Max: 67.76
Current: 38.93
29.85
67.76
Days Payable 59.83
PCRX's Days Payable is ranked lower than
60% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. PCRX: 59.83 )
Ranked among companies with meaningful Days Payable only.
PCRX' s Days Payable Range Over the Past 10 Years
Min: 20.45  Med: 52.63 Max: 246.51
Current: 59.83
20.45
246.51

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.00
PCRX's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. PCRX: -4.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -284.7  Med: -12.6 Max: -3.7
Current: -4
-284.7
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 67.53
PCRX's Price-to-Net-Cash is ranked lower than
90% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. PCRX: 67.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PCRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 14.45  Med: 59.47 Max: 1773.2
Current: 67.53
14.45
1773.2
Price-to-Net-Current-Asset-Value 17.00
PCRX's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. PCRX: 17.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.03  Med: 23.55 Max: 414.29
Current: 17
10.03
414.29
Price-to-Tangible-Book 8.11
PCRX's Price-to-Tangible-Book is ranked lower than
82% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. PCRX: 8.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.1  Med: 9.15 Max: 99.7
Current: 8.11
5.1
99.7
Price-to-Intrinsic-Value-Projected-FCF 26.71
PCRX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. PCRX: 26.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PCRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 26.32  Med: 27.77 Max: 28.1
Current: 26.71
26.32
28.1
Price-to-Median-PS-Value 0.59
PCRX's Price-to-Median-PS-Value is ranked higher than
79% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. PCRX: 0.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 1.03 Max: 2.51
Current: 0.59
0.05
2.51
Earnings Yield (Greenblatt) % 0.85
PCRX's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. PCRX: 0.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -72.7  Med: -2.45 Max: 1.1
Current: 0.85
-72.7
1.1

More Statistics

Revenue (TTM) (Mil) $321.24
EPS (TTM) $ -0.10
Beta1.29
Volatility60.31%
52-Week Range $26.95 - 55.00
Shares Outstanding (Mil)41.11

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 332 376 425 474
EBIT (Mil $) 25 36 53 76
EBITDA (Mil $)
EPS ($) -0.13 0.64 1.59 2.30
EPS without NRI ($) -0.13 0.64 1.59 2.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}